ReviewNeuroprotection (Chichester, England)2026
Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990-2021).
Review in Neuroprotection (Chichester, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global trends in epilepsy and the Chinese experience: Epidemiological transitions, underlying mechanisms, and integrated strategies (1990-2021).Neuroprotection (Chichester, England) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy represents a global public health challenge, with its burden distribution profoundly illuminating patterns of health inequality. Based on the Global Burden of Disease Study 2021 (GBD 2021) data, this review constructs a three-dimensional analytical framework encompassing biological determinants, health system performance, and social determinants of health. Over the past three decades, although the absolute number of individuals with epilepsy worldwide has continued to increase, age-standardized mortality rates have declined substantially. However, 87.9% of the associated disability-adjusted life years (DALYs) are concentrated in low- and lower-middle-income countries (LMICs). China, with approximately 9-10 million people living with epilepsy, confronts a triple disparity encompassing regional disparities, urban-rural gaps, and health system hierarchy barriers: mortality rates in western provinces are approximately nine times higher than those in eastern regions; the treatment gap in rural areas reaches 60%-90%; and primary care capacity deficits within the tiered diagnosis and treatment system create bottlenecks in case identification and referral. Concurrently, the disease spectrum is undergoing a profound transition, with an increasing burden of post-stroke epilepsy in older adults, while special populations, including children and women, continue to face persistent challenges. Despite China's notable achievements in reducing mortality and establishing a tertiary epilepsy center network, multiple interacting factors perpetuate a vicious cycle of poverty, disease, and stigma among affected individuals. Future efforts require alignment with the World Health Organization Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031 (IGAP) to develop precision prevention and control strategies, thereby contributing the Chinese experience to global epilepsy governance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.